Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
J Med Chem ; 50(25): 6367-82, 2007 Dec 13.
Artículo en Inglés | MEDLINE | ID: mdl-17994684

RESUMEN

Indomethacin, a nonselective cyclooxygenase (COX) inhibitor, was modified in three distinct regions in an attempt both to increase cyclooxygenase-2 (COX-2) selectivity and to enhance drug safety by covalent attachment of an organic nitrate moiety as a nitric oxide donor. A human whole-blood COX assay shows the modifications on the 3-acetic acid part of the indomethacin yielding an amide-nitrate derivative 32 and a sulfonamide-nitrate derivative 61 conferred COX-2 selectivity. Along with their respective des-nitrate analogs, for example, 31 and 62, the nitrates 32 and 61 were effective antiinflammatory agents in the rat air-pouch model. After oral dosing, though, only 32 increased nitrate and nitrite levels in rat plasma, indicating that its nitrate tether served as a nitric oxide donor in vivo. In a rat gastric injury model, examples 31 and 32 both show a 98% reduction in gastric lesion score compared to that of indomethacin. In addition, the nitrated derivative 32 inducing 85% fewer gastric lesions when coadministered with aspirin as compared to the combination of aspirin and valdecoxib.


Asunto(s)
Inhibidores de la Ciclooxigenasa 2/síntesis química , Indometacina/análogos & derivados , Indometacina/síntesis química , Donantes de Óxido Nítrico/síntesis química , Animales , Aspirina/efectos adversos , Celecoxib , Inhibidores de la Ciclooxigenasa 2/efectos adversos , Inhibidores de la Ciclooxigenasa 2/farmacología , Diseño de Fármacos , Sinergismo Farmacológico , Femenino , Mucosa Gástrica/patología , Humanos , Ácidos Hidroxámicos/efectos adversos , Ácidos Hidroxámicos/síntesis química , Ácidos Hidroxámicos/farmacología , Indometacina/efectos adversos , Indometacina/farmacología , Masculino , Donantes de Óxido Nítrico/efectos adversos , Donantes de Óxido Nítrico/farmacología , Pirazoles/farmacología , Ratas , Ratas Sprague-Dawley , Úlcera Gástrica/inducido químicamente , Úlcera Gástrica/patología , Relación Estructura-Actividad , Sulfonamidas/farmacología
2.
Pulm Pharmacol Ther ; 20(1): 90-7, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-16481206

RESUMEN

This investigation examined a possible correlation between lipopolysaccharide (LPS)-induced pulmonary neutrophilia and cough. Conscious male guinea pigs were acutely exposed to aerosolized LPS and thereafter at various times challenged with citric acid aerosol (CA; 250mM) to induce cough followed by bronchoalveolar lavage (BAL) to quantitate inflammatory cell accumulation. LPS caused a hyporesponsive cough at 24h post-LPS with neutrophilia apparent from 2h post-LPS. By 96h post-LPS both cough and neutrophilia had returned towards normal. Dexamethasone (DEX, 2mgkg(-1)/day for 3 days prior) did not affect the cough hyporesponsiveness at 24h; however it attenuated LPS-induced BAL fluid neutrophilia. Since LPS can stimulate inducible nitric oxide synthase (iNOS) we hypothesized that the cough hyporesponsiveness may involve nitric oxide. To investigate this we treated animals with an aerosolized iNOS inhibitor 1400W (1mM) immediately prior to LPS. 1400W had no significant effect on either cough hyporesponsiveness or BAL fluid neutrophilia at 24h post-LPS. Despite differing effects on neutrophilia, these findings clearly indicate that neither DEX nor iNOS inhibition had any direct effect on LPS-induced cough hyporesponsiveness. The mechanism underlying the LPS-induced cough hyporesponsiveness does not appear to be directly linked to LPS-induced neutrophilic inflammation.


Asunto(s)
Amidinas/uso terapéutico , Antiinflamatorios/uso terapéutico , Bencilaminas/uso terapéutico , Tos/prevención & control , Dexametasona/uso terapéutico , Enfermedades Pulmonares/prevención & control , Neutrófilos/efectos de los fármacos , Administración por Inhalación , Aerosoles , Amidinas/administración & dosificación , Animales , Antiinflamatorios/administración & dosificación , Bencilaminas/administración & dosificación , Líquido del Lavado Bronquioalveolar/citología , Ácido Cítrico/administración & dosificación , Ácido Cítrico/toxicidad , Tos/inducido químicamente , Dexametasona/administración & dosificación , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/administración & dosificación , Inhibidores Enzimáticos/uso terapéutico , Cobayas , Inyecciones Intraperitoneales , Lipopolisacáridos/administración & dosificación , Lipopolisacáridos/inmunología , Lipopolisacáridos/toxicidad , Enfermedades Pulmonares/inducido químicamente , Enfermedades Pulmonares/inmunología , Masculino , Nebulizadores y Vaporizadores , Infiltración Neutrófila/efectos de los fármacos , Neutrófilos/inmunología , Neutrófilos/patología , Óxido Nítrico Sintasa de Tipo II/antagonistas & inhibidores , Óxido Nítrico Sintasa de Tipo II/genética , Óxido Nítrico Sintasa de Tipo II/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Factores de Tiempo
3.
Inflammopharmacology ; 12(5-6): 521-34, 2005.
Artículo en Inglés | MEDLINE | ID: mdl-16259719

RESUMEN

Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to treat inflammation and to provide pain relief but suffer from a major liability concerning their propensity to cause gastric damage. As nitric oxide (NO) is known to be gastro-protective we have synthesized a NO-donating prodrug of naproxen named NMI-1182. We evaluated two cyclo-oxygenase (COX)-inhibiting nitric oxide donors (CINODs), NMI-1182 and AZD3582, for their ability to be gastro-protective compared to naproxen and for their anti-inflammatory activity. NMI-1182 and AZD3582 were found to produce similar inhibition of COX activity to that produced by naproxen. Both NMI-1182 and AZD3582 produced significantly less gastric lesions after oral administration than naproxen. All three compounds effectively inhibited paw swelling in the rat carrageenan paw edema model. In the carrageenan air pouch model all three compounds significantly reduced PGE2 levels in the pouch exudate but only NMI-1182 and naproxen inhibited leukocyte influx. These data demonstrate that NMI-1182 has comparable anti-inflammatory activity to naproxen but with a much reduced likelihood to cause gastric damage.


Asunto(s)
Inhibidores de la Ciclooxigenasa/farmacología , Naftalenos/farmacología , Donantes de Óxido Nítrico/farmacología , Sustancias Protectoras/farmacología , Animales , Antiinflamatorios/sangre , Antiinflamatorios/química , Antiinflamatorios/farmacología , Aorta Abdominal/efectos de los fármacos , Aorta Abdominal/fisiología , Carragenina , Ciclooxigenasa 1/sangre , Ciclooxigenasa 2/sangre , Inhibidores de la Ciclooxigenasa/sangre , Inhibidores de la Ciclooxigenasa/química , Dinoprostona/antagonistas & inhibidores , Dinoprostona/metabolismo , Relación Dosis-Respuesta a Droga , Edema/inducido químicamente , Edema/prevención & control , Mucosa Gástrica/efectos de los fármacos , Mucosa Gástrica/metabolismo , Mucosa Gástrica/patología , Humanos , Técnicas In Vitro , Inflamación/inducido químicamente , Inflamación/prevención & control , Masculino , Estructura Molecular , Naftalenos/sangre , Naftalenos/química , Naproxeno/sangre , Naproxeno/química , Naproxeno/farmacología , Infiltración Neutrófila/efectos de los fármacos , Donantes de Óxido Nítrico/sangre , Donantes de Óxido Nítrico/química , Sustancias Protectoras/química , Ratas , Ratas Sprague-Dawley , Vasodilatación/efectos de los fármacos
4.
Biochem Pharmacol ; 70(9): 1343-51, 2005 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-16168964

RESUMEN

Cyclooxygenase (COX, EC 1.14.99.1) inhibitor-nitric oxide (NO) donor (CINOD) hybrid compounds represent an attractive alternative to NSAID and coxib therapy. This report compares two CINODs, NMI-1182 (naproxen-glyceryl dinitrate) and AZD3582 (naproxen-n-butyl nitrate), for their ability to inhibit COX-1 and -2, deliver bioavailable nitric oxide, and release naproxen, using in vitro biochemical and pharmacological methods. In human whole blood, both CINODs showed inhibition, comparable to naproxen, of both COX isozymes and slowly released naproxen. Both CINODs donated bioavailable NO, as detected by cGMP induction in the pig kidney transformed cell line, LLC-PK1, but NMI-1182 was more potent by 30-100 times than AZD3582, GTN, GDN, and ISDN and considerably faster in inducing cGMP synthesis than AZD3582. The nitrate groups of GTN, NMI-1182, and AZD3582 appeared to be bioactivated via a common pathway, since each compound desensitized LLC-PK1 cells to subsequent challenge with the other compounds. Similar cGMP induction also occurred in normal, untransformed cells (human renal proximal tubule epithelial cells and hepatocytes from man, rat, and monkey); again, NMI-1182 was superior to AZD3582. NMI-1182 was also the more metabolically labile compound, releasing more absolute nitrate and nitrite (total NO(x)) in human stomach (in which NO is salutary) and liver S9 homogenates. Naproxen was also more rapidly freed from NMI-1182 than AZD3582 in human stomach, although liver S9 hydrolyzed both CINODs with similar rates. These in vitro tests revealed that NMI-1182 may be a better CINOD than AZD3582 because of its superior NO donating and naproxen liberating properties.


Asunto(s)
Inhibidores de la Ciclooxigenasa/farmacología , Naftalenos/farmacología , Donantes de Óxido Nítrico/farmacología , GMP Cíclico/biosíntesis , Ciclooxigenasa 1/efectos de los fármacos , Ciclooxigenasa 2/efectos de los fármacos , Humanos , Hígado/metabolismo , Naftalenos/farmacocinética , Naproxeno/farmacología , Óxido Nítrico/biosíntesis
5.
Br J Pharmacol ; 141(2): 233-40, 2004 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-14691051

RESUMEN

1. Current antitussive medications have limited efficacy and often contain the opiate-like agent dextromethorphan (DEX). The mechanism whereby DEX inhibits cough is ill defined. DEX displays affinity at both NMDA and sigma receptors, suggesting that the antitussive activity may involve central or peripheral activity at either of these receptors. This study examined and compared the antitussive activity of DEX and various putative sigma receptor agonists in the guinea-pig citric-acid cough model. 2. Intraperitoneal (i.p.) administration of DEX (30 mg kg(-1)) and the sigma-1 agonists SKF-10,047 (1-5 mg kg(-1)), Pre-084 (5 mg kg(-1)), and carbetapentane (1-5 mg kg(-1)) inhibited citric-acid-induced cough in guinea-pigs. Intraperitoneal administration of a sigma-1 antagonist, BD 1047 (1-5 mg kg(-1)), reversed the inhibition of cough elicited by SKF-10,047. In addition, two structurally dissimilar sigma agonists SKF-10,047 (1 mg ml(-1)) and Pre-084 (1 mg ml(-1)) inhibited cough when administered by aerosol. 3. Aerosolized BD 1047 (1 mg ml(-1), 30 min) prevented the antitussive action of SKF-10,047 (5 mg kg(-1)) or DEX (30 mg kg(-1)) given by i.p. administration and, likewise, i.p. administration of BD 1047 (5 mg kg(-1)) prevented the antitussive action of SKF-10,047 given by aerosol (1 mg ml(-1)). 4. These results therefore support the argument that antitussive effects of DEX may be mediated via sigma receptors, since both systemic and aerosol administration of sigma-1 receptor agonists inhibit citric-acid-induced cough in guinea-pigs. While significant systemic exposure is possible with aerosol administration, the very low doses administered (estimated <0.3 mg kg(-1)) suggest that there may be a peripheral component to the antitussive effect.


Asunto(s)
Antitusígenos/farmacología , Antitusígenos/uso terapéutico , Tos/tratamiento farmacológico , Fenazocina/análogos & derivados , Receptores sigma/agonistas , Animales , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Tos/metabolismo , Dextrometorfano/farmacología , Dextrometorfano/uso terapéutico , Relación Dosis-Respuesta a Droga , Etilenodiaminas/farmacología , Cobayas , Masculino , Fenazocina/farmacología , Fenazocina/uso terapéutico , Unión Proteica/efectos de los fármacos , Unión Proteica/fisiología , Receptores sigma/metabolismo , Receptor Sigma-1
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...